Protalix BioTherapeutics (PLX) Leases (2019 - 2025)
Historic Leases for Protalix BioTherapeutics (PLX) over the last 9 years, with Q3 2025 value amounting to $7.8 million.
- Protalix BioTherapeutics' Leases rose 3835.25% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 3835.25%. This contributed to the annual value of $5.4 million for FY2024, which is 810.63% down from last year.
- Per Protalix BioTherapeutics' latest filing, its Leases stood at $7.8 million for Q3 2025, which was up 3835.25% from $5.0 million recorded in Q2 2025.
- Protalix BioTherapeutics' Leases' 5-year high stood at $7.8 million during Q3 2025, with a 5-year trough of $4.8 million in Q2 2022.
- For the 5-year period, Protalix BioTherapeutics' Leases averaged around $5.5 million, with its median value being $5.4 million (2021).
- The largest annual percentage gain for Protalix BioTherapeutics' Leases in the last 5 years was 3835.25% (2025), contrasted with its biggest fall of 1279.23% (2025).
- Over the past 5 years, Protalix BioTherapeutics' Leases (Quarter) stood at $5.0 million in 2021, then rose by 2.56% to $5.1 million in 2022, then grew by 16.16% to $5.9 million in 2023, then decreased by 8.11% to $5.4 million in 2024, then soared by 43.83% to $7.8 million in 2025.
- Its Leases was $7.8 million in Q3 2025, compared to $5.0 million in Q2 2025 and $5.2 million in Q1 2025.